All In Biotech

Drug Trial Radar · NCT05107336

Study to Assess the Safety, Tolerability, and Pharmacokinetics (Movement of Drugs Within the Body) of AZD2693 in Healthy Participants

A Randomised, Single-Blind, Placebo-Controlled, Phase I Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD2693 Following Multiple Subcutaneous Dose Administration in Healthy Participants

Last checked: Nov 19, 2026Latest source record: Jul 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

44

Actual

Start

Nov 25, 2021

Primary completion

Mar 21, 2023

Study completion Mar 21, 2023

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Nov 4, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Other
FDA-regulated drug
No
Who can join
All sexes, from 20 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This Phase I, randomised, single-blind, placebo-controlled study has been designed to assess the safety, tolerability, and pharmacokinetics (PK) of AZD2693 following subcutaneous (SC) administration of AZD2693 in healthy participants

Conditions

  • Healthy Participants

Interventions

  • AZD2693Drug

    Participants will receive subcutaneous injection of AZD2693, once per month.

  • PlaceboDrug

    Participants will receive subcutaneous injection of placebo (volume matching to AZD2693 injection \[0.9% saline solution\]), once per month.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Until Day 162 (Final/Early termination visit)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Sumida-ku, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.